Clinical Trial Update: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update shows GEN-001 in combination with Avelumab for PD-L1 positive gastric cancer and gastroesophageal junction adenocarcinoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Avelumab (avelumab)
• GEN-001

Snippet

Sponsor: Genome & Company | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED